Tectonic Therapeutic Hits Enrollment Target in PH-HFpEF Trial
Event summary
- Tectonic Therapeutic completed enrollment in its Phase 2 APEX trial for TX45 in PH-HFpEF patients, hitting the target of 191 participants across 14 countries.
- 72% of enrolled patients (137) had the severe CpcPH subtype with PVR >3 WU at baseline, aligning with the trial's design.
- Topline results from the 24-week trial are expected in early Q1 2027.
- TX45 is being tested in two dose regimens against placebo in this randomized, double-blind study.
The big picture
Tectonic's progress in PH-HFpEF represents a push into a high-unmet-need cardiovascular niche where no approved therapies exist. The focus on CpcPH patients with elevated PVR suggests a strategic bet on treating the most severe subset first. Success here could validate Tectonic's GPCR-modulating platform technology, potentially unlocking broader applications in pulmonary vascular diseases.
What we're watching
- Clinical Efficacy
- Whether TX45 demonstrates meaningful reductions in PVR and other clinical endpoints in the severe CpcPH patient subset.
- Regulatory Pathway
- How the Phase 2 results might position TX45 for potential accelerated development given the unmet need in PH-HFpEF.
- Competitive Landscape
- The pace at which Tectonic can differentiate TX45 from existing PAH therapies repurposed for Group 2 PH.
Related topics